Most Read Articles
Jackey Suen, 15 Oct 2018

Prognostic nutrition index (PNI) strongly predicts clinical outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC), according to two studies presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018).

Brentuximab vedotin: A CD30-positive targeted therapy in a heavily pretreated relapsed or refractory Hodgkin lymphoma

19 Sep 2018
Kanker darah, seperti leukemia, Hodgkin lymphona, non-Hodgkin lymphoma dan multiple myeloma
Brentuximab vedotin (ADCETRIS®; Takeda Pharmaceuticals) is an antibody-drug conjugate that selectively delivers monomethyl auristatin E, a very potent antimicrotubule agent,into CD30-positive tumour cells, leading to the disruption of the microtubule network. This results in cell cycle arrest and apoptotic death of the CD30-positive cells, making brentuximab vedotin a promising anticancer agent.6,7

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jackey Suen, 15 Oct 2018

Prognostic nutrition index (PNI) strongly predicts clinical outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC), according to two studies presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018).